IRF4 and plasma cell myeloma: Because transcription factors are extremely difficult to target with small inhibitors, we prevented IRF4 transcription with an IRF4‐selective ASO that could be directly delivered into cells through free uptake and has shown efficacy in cancers such as multiple myeloma.45